1. Scrip
  2. >>Focus On Asia
  3. >>India

Novartis invites applications for BioCamp India

 
• By Anju Ghangurde

Novartis India is hosting its first Biotechnology Leadership Camp (BioCamp), a seminar for postgraduate students and young researchers in science, pharmacology, medicine, biotechnology, business management or law, in Hyderabad on August 11th-12th. Selected students will have the opportunity to learn from and network with leaders in the pharmaceutical and biotechnology sectors, as well as hone their team-building skills. The top two students from BioCamp India will represent the country at the International BioCamp, which is being held at the Novartis Institute of BioMedical Research, Cambridge, US, from October 27th–31st. The final date for applications is July 10th. For more information, email: biocamp.india@novartis.com.

Novartis India is hosting its first Biotechnology Leadership Camp (BioCamp), a seminar for postgraduate students and young researchers in science, pharmacology, medicine, biotechnology, business management or law, in Hyderabad on August 11th-12th. Selected students will have the opportunity to learn from and network with leaders in the pharmaceutical and biotechnology sectors, as well as hone their team-building skills. The top two students from BioCamp India will represent the country at the International BioCamp, which is being held at the Novartis Institute of BioMedical Research, Cambridge, US, from October 27th–31st. The final date for applications is July 10th. For more information, email:

.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 
• By Anju Ghangurde

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

More from Focus On Asia

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.